New therapy shown to improve progression-free survival and shrink tumors in rare cancer for the first time
Sunday, June 2, 2013 - 10:30
in Health & Medicine
The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new research.